Biotech Daily

Monday July 27, 2026

Daily news on ASX-listed biotechnology companies

*** ASX UP, BIOTECH DOWN: 4D MEDICAL UP 5.5%; EBR DOWN 18%**

*** RADIOPHARM $12.5m PLACEMENT; $6m SHARE PLAN TO GO**

*** BLS UNAUDITED REVENUE UP 146% TO $75m**

*** LUMOS RECEIPTS UP 180% TO $25.5m**

*** PROTEOMICS RECEIPTS UP 173% TO $2.2m**

*** IMRICOR: RADY CHILDREN'S 1st US NORTHSTAR ORDER**

*** IMUGENE 3rd I BTK INHIBITOR, AZER-CEL BLOOD CANCER RESPONSE**

*** AROA 1.1m M-D STOCK, 47% DIRECTOR FEE HIKE AGM**

*** IMUGENE LOSES 11-YEAR M-D LESLIE CHONG**

MARKET REPORT

The Australian stock market was up 1.39 percent on Monday July 27, 2026, with the ASX200 up 121.7 points to 8,894.0 points.

Twelve of the Biotech Daily Top 40 companies were up, 18 fell and 10 traded unchanged. All four Big Caps were up.

4D Medical was the best, up 17 cents or 5.5 percent to $3.28, with 4.4 million shares traded. Compumedics, Imricor and Nova Eye climbed four percent or more; Aroa, Emvision, Paradigm and Proteomics were up three percent or more; Cochlear and Resmed rose more than two percent; CSL, Neuren, Pro Medicus, Racura and Saluda were up one percent or more; with Nanosonics up by 0.3 percent.

EBR led the falls, down 5.5 cents or 18.3 percent to 24.5 cents, with 22.6 million shares traded.

Lumos lost 9.1 percent; both Botanix and Prescient were down 8.7 percent; Amplia shed 7.1 percent; Clarity was down 5.1 percent; Medical Developments and Polynovo fell four percent or more; Alcidion, Cyclopharm, Mesoblast and Optiscan were down more than three percent; Actinogen, Clinuvel, Dimerix and Telix shed two percent or more; with Artrya and Avita down by less than one percent.

RADIOPHARM THERANOSTICS

Radiopharm says it has “firm commitments” to raise $12.5 million in a placement, with a further $6 million, partly-underwritten share purchase plan to follow.
Radiophrm said the placement comprised a $6.7 million placement to Australian investors at an issue price of 1.5 cents a share and a $US4.1 million ($A5.8 million) placement to US investors at an issue price of $US3.16 ($A4.51) per American depository share (ADS), with each ADS representing 300 ordinary shares.
The company said the Australian placement price was a 23.1 percent discount to the 15-day volume weighted average price and that the share purchase plan offer price would be the lower of the placement price and a 2.5 percent discount to the five-day volume weighted average price prior to the closing date.
Radiopharm said investors under the Australian placement and share plan would receive one option for every share subscribed for, exercisable at 1.8 cents each by July 31, 2029.
The company said for every ADS acquired in the US placement, investors would receive one American depository receipt (ADR) warrant in lieu of attaching options, exercisable at $US3.79 each by July 31, 2029.
Radiopharm said the funds raised would be used to begin a registrational, phase III study of RAD101, complete its RAD204 dose escalation study and progress its RAD202, RAD402 and RV01 therapeutic programs, as well as support partnering initiatives.
The company said it had “commitments from investors” to subscribe for up-to $3 million of shortfall under the share purchase plan.
Radiopharm said Bell Potter was lead manager and bookrunner to the capital raising, with HC Wainwright and CO acting as placement agent to the US offer.
The company said the share plan had a record date of July 23, would open on August 7 and close on September 10, 2026.
Radiopharm fell half a cent or 26.3 percent to 1.4 cents with 46.35 million shares traded.

BLS PHARMACEUTICALS (FORMERLY BIOXYNE)

BLS says unaudited revenue for the year to June 30, 2026 rose 146.3 percent to $74.98 million, “the top end of the company’s guidance range of $65-to-75 million”.
Last year, the then Bioxyne said record revenue for the year to June 30, 2025 was up 215.3 percent to $30,446,751, with a $4,901,181 profit (BD: Aug 29, 2025).
Today, the company, BLS, or Breath Life Sciences, said customer receipts for the year from sales of its marijuana production contracts, marijuana, psilocybin and 3,4-methylene-dioxy-meth-amphetamine-based (MDMA) products and probiotic Lactobacillus fermentum were up 125.2 percent to $72,923,000, compared to the prior corresponding period.
BLS said increased revenue was “driven by strong performance across the Australian business, expanding international sales into Europe, continued growth in white label pharmaceutical manufacturing, increasing demand for regulated therapeutic products and the commencement of new international commercial agreements”.
BLS managing-director Sam Watson said 2025-’26 was “a defining year”.
“We met the top end of our financial guidance while continuing to expand internationally and strengthen every part of our pharmaceutical manufacturing platform,” Mr Watson said.
“We believe 2026-’27 provides another significant opportunity to build on this momentum,” Mr Watson said.
The company said it had a positive cash flow of $6,291,000 for the three months, “the strongest result reported by the company to date”, with cash and cash equivalents of $13,258,000 at June 30, 2026 compared to $7,668,000 at June 30, 2025.
BLS fell 2.5 cents or three percent to 81.5 cents.

LUMOS DIAGNOSTICS

Lumos says customer receipts for the year to June 30, 2026 were up 180.2 percent to $US17,842,000 ($A25,498,000), compared to the prior corresponding period.
Lumos said that its unaudited revenue for the year to June 30, 2026 from sales of the finger-rick Febridx blood test for differentiating bacterial from viral respiratory infections, as well as sales of its third-party supplied Cordx influenza and Covid-19 combination test, and its services business was up 6.4 percent to $US13,192,000, compared to the previous corresponding period.
The company said receipts for the three months were up 283.5 percent to $US6,979,000, including a $US5.0 million pre-payment under its Phase Scientific licencing agreement following a US Food and Drug Administration clinical laboratory improvement amendment (CLIA) waiver for Febridx.
Last year, Lumos said it had an up-to $US317 million, six-year distribution and supply deal with Hong Kong's Phase Scientific International for Febridx (BD: Jul 16, 2025).
In 2023, the company said it had FDA 510(k) clearance to market its Febridx rapid, point-of-care, finger-prick, blood test (BD: Jul 3, 2023).
Earlier this year, Lumos said that the FDA had granted a CLIA waiver for its Febridx test (BD: Mar 27, 2026).
Today, the company said Febridx revenue was up 875 percent from $400,000 to about $US3,900,000, primarily due to sales orders from Phase Scientific.
Lumos said that the third-party supplied Cordx test introduced as a replacement for its Viradx test "following its loss of price competitiveness".
The company said Cordx sales were $US200,000 and "unable to match the sales levels achieved by Viradx in the [prior corresponding period]", with a decline in services business revenue "primarily attributable to the extension of the Hologic fFN [foetal fibronectin test] project timeline".
In 2024, Lumos said the Marlborough, Massachusetts-based Hologic Inc would pay it up-to $US10.0 million to improve their women's health products and adapt them for use with its platform (BD: Jan 21, 2024).
Today, the company said it had a positive cash flow of $US2,679,000 for the three months to June 30, 2026.
Lumos said that it had cash and cash equivalents of $US15,429,000 at June 30, 2026 compared to $US1,956,000 at June 30, 2025.
Lumos fell one cent or 9.1 percent to 10 cents with 5.2 million shares traded.

PROTEOMICS INTERNATIONAL LABORATORIES

Proteomics says customer receipts for the year to June 30, 2026 were up 173.0 percent to $2,247,000, compared to the previous corresponding period.
Proteomics said receipts for the three months to June 30, 2026 from sales of its Promarker portfolio of blood tests including Promarker D for kidney disease fell 36.3 percent to $128,000, compared to the prior corresponding period.
The company said that it had a cash burn of $2,088,000 for the three months to June 30, 2026.
Proteomics said that it had cash and cash equivalents of $3,500,000 at June 30, 2026 compared to $11,037,000 at June 30, 2025, leaving it with 1.7 quarters of cash.
Proteomics said the three months loss included non-recurring redundancy costs and entitlements of about $462,000 related to an organizational restructure, expected to receive a research and development tax incentive and would reduce costs.
Proteomics was up half a cent or 3.2 percent to 16 cents.

IMRICOR MEDICAL SYSTEMS

Imricor says it has begun US commercialization with a first purchase order from San Diego's Rady Children's Hospital for its Northstar interventional MRI mapping system.
Earlier this year, Imricor said it had US Food and Drug Administration 510(k) clearance for its Vision-magnetic resonance (MR) diagnostic catheter, its first FDA clearance; and later, said it had FDA 510(k) clearance for its Northstar 3-dimensional magnetic resonance imaging (MRI) mapping and guidance system (BD: Jan 18, 29, 2026).
Earlier this month, the company said it had FDA 510(k) clearance for a paediatric label expansion of its Northstar and Vision-MR systems (BD: Jul 2, 2026).
Today, Imricor said Rady Children's was "home to one of the leading paediatric cardiology programs in the US and will be the first US hospital to commit to delivering cardiac catheterization procedures guided by Northstar in a 100 percent radiation-free [interventional MR] setting".
The company did not disclose the commercial terms of the agreement.
Imricor said several additional US hospitals were "in the final stages of their purchasing processes and are expected to purchase Northstar over the coming weeks".
Imricor said it was adding sales manager for the southeast US, with additional sales staff and internal sales operations personnel "to support the growth over the coming months".
Imricor executive chair Steve Wedan said it was meaningful "that the first patients in the US to benefit from our products, outside of clinical trials, are children".
Imricor was up eight cents or 4.2 percent to $2.00 with 954,034 shares traded.

IMUGENE

Imugene says a third patient has had a partial response in the Bruton tyrosine kinase (BTK) inhibitor cohort of its phase I study of azer-cel for various forms of blood cancer.
Earlier this year, Imugene said it enrolled the first BTK inhibitor patient in its phase Ib basket study of its azer-cel CAR-T for various blood cancers (BD: May 28, 2026).
Last month, the company said one follicular lymphoma patient in the BTK inhibitor cohort of the study had achieved a complete response; and later, said a second patient with mantle sell lymphoma had a complete response (BD: Jun 30, Jul 1, 2026).
Today, Imugene said the third patient with a partial response was the second follicular lymphoma patient in the cohort and had previously progressed on BTK inhibitor therapy.
The company said five patients had been dosed in the phase I, BTK inhibitor cohort to-date, with further updates to be provided as additional data was available.
Imugene was unchanged at nine cents with 6.3 million shares traded.

AROA BIOSURGERY

Aroa says investors will vote to issue managing-director Brian Ward 377,742 restricted stock and 726,559 performance shares and increase the director fees by 46.7 percent.
Aroa said its annual general meeting would vote to issue Mr Ward a deferred short-term incentive of 377,742 restricted stock units, valued at $NZ295,250 ($A245,000) and a long-term incentive of 726,559 performance share rights, valued at $NZ568,000 ($A470,000).
The company said the incentive was in addition to Mr Ward's $NZ574,364 fixed yearly remuneration, not including superannuation.
Aroa said investors would vote to increase the aggregate fees for non-executive directors by 46.7 percent to $NZ1,100,000, and elect Dr Mohr and Mr Shearer as directors.
The meeting will be held online on August 19, 2026 at 9am (AEST).
Aroa was up two cents or 3.6 percent to 58 cents.

IMUGENE

Imugene says “after nearly 11 years” Leslie Chong will step down as chief executive officer and managing-director “for personal reasons”, effective immediately.

Imugene said Ms Chong had “agreed to remain available to assist with the transitioning to new leadership and to support the company on matters that may benefit from her long [chief executive officer] tenure”.

The company said going forward the leadership team would report to executive chair Paul Hopper “until new leadership commences with the company”.

Ms Chong said “while personal reasons require me to step back from my day-to-day duties immediately, I do so with confidence in Imugene’s future and remain fully committed to supporting the company in any way that may be helpful going forward”.

Mr Hopper thanked Ms Chong for her “dedication and significant contribution to Imugene and wish her every success for the future’.